US 2021/0061902 A1 · ANTI-IL-2 ANTIBODIES AND COMPOSITIONS AND USES THEREOF

Abstract

The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

Claims23

Dependent claims

1-6. (canceled)

An isolated antibody or antigen-binding portion thereof that specifically binds human IL-2, said antibody comprising:

(i) (a) a HCDR1 comprising SEQ ID NO:
73, 74, or 75;
a HCDR2 comprising SEQ ID NO:
76, or 77;
a HCDR3 comprising SEQ ID NO:
78;
a LCDR1 comprising SEQ ID NO:
79;
a LCDR2 comprising SEQ ID NO:
80;
and a LCDR3 comprising SEQ ID NO:
81;
(b) a HCDR1 comprising SEQ ID NO:
82, 83, or 84;
a HCDR2 comprising SEQ ID NO:
85, or 86;
a HCDR3 comprising SEQ ID NO:
87;
a LCDR1 comprising SEQ ID NO:
88;
a LCDR2 comprising SEQ ID NO:
89;
and a LCDR3 comprising SEQ ID NO:
90;
(c) a HCDR1 comprising SEQ ID NO:
91, 92, or 93;
a HCDR2 comprising SEQ ID NO:
94, or 95;
a HCDR3 comprising SEQ ID NO:
96;
a LCDR1 comprising SEQ ID NO:
97;
a LCDR2 comprising SEQ ID NO:
98;
and a LCDR3 comprising SEQ ID NO:
99;
(d) a HCDR1 comprising SEQ ID NO:
100, 101, or 102;
a HCDR2 comprising SEQ ID NO:
103, or 104;
a HCDR3 comprising SEQ ID NO:
105;
a LCDR1 comprising SEQ ID NO:
106;
a LCDR2 comprising SEQ ID NO:
107;
and a LCDR3 comprising SEQ ID NO:
108;
(e) a HCDR1 comprising SEQ ID NO:
109, 110, or 111;
a HCDR2 comprising SEQ ID NO:
112, or 113;
a HCDR3 comprising SEQ ID NO:
114;
a LCDR1 comprising SEQ ID NO:
115;
a LCDR2 comprising SEQ ID NO:
116;
and a LCDR3 comprising SEQ ID NO:
117;
(f) a HCDR1 comprising SEQ ID NO:
118, 119, or 120;
a HCDR2 comprising SEQ ID NO:
121, or 122;
a HCDR3 comprising SEQ ID NO:
123;
a LCDR1 comprising SEQ ID NO:
124;
a LCDR2 comprising SEQ ID NO:
125;
and a LCDR3 comprising SEQ ID NO:
126;
(g) a HCDR1 comprising SEQ ID NO:
127, 128, or 129;
a HCDR2 comprising SEQ ID NO:
130, or 131;
a HCDR3 comprising SEQ ID NO:
132;
a LCDR1 comprising SEQ ID NO:
133;
a LCDR2 comprising SEQ ID NO:
134;
and a LCDR3 comprising SEQ ID NO:
135;
(h) a HCDR1 comprising SEQ ID NO:
136, 137, or 138;
a HCDR2 comprising SEQ ID NO:
139, or 140;
a HCDR3 comprising SEQ ID NO:
141;
a LCDR1 comprising SEQ ID NO:
142;
a LCDR2 comprising SEQ ID NO:
143;
and a LCDR3 comprising SEQ ID NO:
144;
(i) a HCDR1 comprising SEQ ID NO:
145, 146, or 147;
a HCDR2 comprising SEQ ID NO:
148, or 149;
a HCDR3 comprising SEQ ID NO:
150;
a LCDR1 comprising SEQ ID NO:
151;
a LCDR2 comprising SEQ ID NO:
152;
and a LCDR3 comprising SEQ ID NO:
153;
(j) a HCDR1 comprising SEQ ID NO:
154, 155, or 156;
a HCDR2 comprising SEQ ID NO:
157, or 158;
a HCDR3 comprising SEQ ID NO:
159;
a LCDR1 comprising SEQ ID NO:
160;
a LCDR2 comprising SEQ ID NO:
161;
and a LCDR3 comprising SEQ ID NO:
162;
(k) a HCDR1 comprising SEQ ID NO:
163, 164, or 165;
a HCDR2 comprising SEQ ID NO:
166, or 167;
a HCDR3 comprising SEQ ID NO:
168;
a LCDR1 comprising SEQ ID NO:
169;
a LCDR2 comprising SEQ ID NO:
170;
and a LCDR3 comprising SEQ ID NO:
171;
(l) a HCDR1 comprising SEQ ID NO:
172, 173, or 174;
a HCDR2 comprising SEQ ID NO:
175, or 176;
a HCDR3 comprising SEQ ID NO:
177;
a LCDR1 comprising SEQ ID NO:
178;
a LCDR2 comprising SEQ ID NO:
179;
and a LCDR3 comprising SEQ ID NO:
180;
(m) a HCDR1 comprising SEQ ID NO:
181, 182, or 183;
a HCDR2 comprising SEQ ID NO:
184, or 185;
a HCDR3 comprising SEQ ID NO:
186;
a LCDR1 comprising SEQ ID NO:
187;
a LCDR2 comprising SEQ ID NO:
188;
and a LCDR3 comprising SEQ ID NO:
189;
(n) a HCDR1 comprising SEQ ID NO:
190, 191, or 192;
a HCDR2 comprising SEQ ID NO:
193, or 194;
a HCDR3 comprising SEQ ID NO:
195;
a LCDR1 comprising SEQ ID NO:
196;
a LCDR2 comprising SEQ ID NO:
197;
and a LCDR3 comprising SEQ ID NO:
198;
(o) a HCDR1 comprising SEQ ID NO:
199, 200, or 201;
a HCDR2 comprising SEQ ID NO:
202, or 203;
a HCDR3 comprising SEQ ID NO:
204;
a LCDR1 comprising SEQ ID NO:
205;
a LCDR2 comprising SEQ ID NO:
206;
and a LCDR3 comprising SEQ ID NO:
207;
(p) a HCDR1 comprising SEQ ID NO:
208, 209, or 210;
a HCDR2 comprising SEQ ID NO:
211, or 212;
a HCDR3 comprising SEQ ID NO:
213;
a LCDR1 comprising SEQ ID NO:
214;
a LCDR2 comprising SEQ ID NO:
215;
and a LCDR3 comprising SEQ ID NO:
216;
or
(q) a HCDR1 comprising SEQ ID NO:
217;
a HCDR2 comprising SEQ ID NO:
218;
a HCDR3 comprising SEQ ID NO:
219;
a LCDR1 comprising SEQ ID NO:
220;
a LCDR2 comprising SEQ ID NO:
221;
and a LCDR3 comprising SEQ ID NO:
222;
(ii) a heavy chain variable domain (VH) comprising:
a) an HCDR3 in SEQ ID NO:
1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 71 as shown in Table 7;
or
b) HCDR1-3 in SEQ ID NO:
1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 71 as shown in Table 7;
(iii) a light chain variable domain (VL) comprising:
a) an LCDR3 in SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, or 72 as shown in Table 7;
or
b) LCDR1-3 in SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, or 72 as shown in Table 7;
(iv) a heavy chain variable domain (VH) comprising:
a) an HCDR3 in SEQ ID NO:
1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or 71 as shown in Table 7;
b) HCDR1-3 in SEQ ID NO:
1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or 71 as shown in Table 7;
or
c) the amino acid sequence of SEQ ID NO:
1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or 71;
(v) a light chain variable domain (VL) comprising:
a) an LCDR3 in SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 72 as shown in Table 7;
b) LCDR1-3 in SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 72 as shown in Table 7;
or
c) the amino acid sequence of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 72;
(vi) the HCDR1-3 and LCDR1-3 amino acid sequences as shown in:
a) SEQ ID NOs:
1 and 2, respectively;
b) SEQ ID NOs:
3 and 4, respectively;
c) SEQ ID NOs:
5 and 6, respectively;
d) SEQ ID NOs:
7 and 8, respectively;
e) SEQ ID NOs:
9 and 10, respectively;
f) SEQ ID NOs:
11 and 12, respectively;
g) SEQ ID NOs:
13 and 14, respectively;
h) SEQ ID NOs:
15 and 16, respectively;
i) SEQ ID NOs:
17 and 18, respectively;
j) SEQ ID NOs:
19 and 20, respectively;
k) SEQ ID NOs:
21 and 22, respectively;
l) SEQ ID NOs:
23 and 24, respectively;
m) SEQ ID NOs:
25 and 26, respectively;
n) SEQ ID NOs:
27 and 28, respectively;
o) SEQ ID NOs:
29 and 30, respectively;
p) SEQ ID NOs:
31 and 32, respectively;
or
q) SEQ ID NOs:
71 and 72, respectively;
as shown in Table 7;
(vii) the amino acid sequences as shown in:
a) SEQ ID NOs:
1 and 2, respectively;
b) SEQ ID NOs:
3 and 4, respectively;
c) SEQ ID NOs:
5 and 6, respectively;
d) SEQ ID NOs:
7 and 8, respectively;
e) SEQ ID NOs:
9 and 10, respectively;
f) SEQ ID NOs:
11 and 12, respectively;
g) SEQ ID NOs:
13 and 14, respectively;
h) SEQ ID NOs:
15 and 16, respectively;
i) SEQ ID NOs:
17 and 18, respectively;
j) SEQ ID NOs:
19 and 20, respectively;
k) SEQ ID NOs:
21 and 22, respectively;
l) SEQ ID NOs:
23 and 24, respectively;
m) SEQ ID NOs:
25 and 26, respectively;
n) SEQ ID NOs:
27 and 28, respectively;
o) SEQ ID NOs:
29 and 30, respectively;
p) SEQ ID NOs:
31 and 32, respectively;
or
q) SEQ ID NOs:
71 and 72, respectively.

303 more elements

Dependencies are inferred from the claim text.

Anti-il-2 antibodies and compositions and uses thereof

Life of this patent

Anti-il-2 antibodies and compositions and uses thereof

Life of this patent

Abstract

Claims23